Xeltis AG - Product Pipeline Analysis, 2018 Update

  • ID: 4395081
  • Company Profile
  • 26 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Abionic SA
  • Sequana Medical AG
  • Symetis SA
  • MORE
Xeltis AG (Xeltis) is a clinical-stage medical equipment company that harnesses advances in science to improve the treatment of heart valve related conditions. The company’s polymer-based technology platform, RestoreX, facilitates the natural restoration of heart valve through a process referred to as endogenous tissue restoration (ETR). Based on supramolecular chemistry, the company develops bioabsorbable synthetic heart valves and vascular grafts to replace defective heart valves and blood vessels. ETR enables the patient’s natural healing system to develop tissue that spreads into the heart valve of Xeltis, building a new and natural valve inside with full functionality. The implants of Xeltis get absorbed by the body in the course of time. The company also operates research and development centers, manufacturing facility in Eindhoven, the Netherlands. Xeltis is headquartered in Zurich, Switzerland.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Xeltis AG
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abionic SA
  • Sequana Medical AG
  • Symetis SA
  • MORE
Xeltis AG Company Overview
Xeltis AG Company Snapshot
Xeltis AG Pipeline Products and Ongoing Clinical Trials Overview
Xeltis AG – Pipeline Analysis Overview
Xeltis AG - Key Facts
Xeltis AG - Major Products and Services
Xeltis AG Pipeline Products by Development Stage
Xeltis AG Ongoing Clinical Trials by Trial Status
Xeltis AG Pipeline Products Overview
Endogenous Tissue Restoration (ETR) Cardiovascular Graft
Endogenous Tissue Restoration (ETR) Cardiovascular Graft Product Overview
Transcatheter Aortic Heart Valve
Transcatheter Aortic Heart Valve Product Overview
Xeltis Pulmonary Valve
Xeltis Pulmonary Valve Product Overview
Xeltis Pulmonary Valve Clinical Trial
Xeltis AG - Key Competitors
Xeltis AG - Key Employees
Xeltis AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Xeltis AG, Recent Developments
Jun 25, 2018: The Children’s Hospital of Pittsburgh of UPMC joins the Xplore-2 trial
Jun 22, 2018: Children’s Hospital Los Angeles joins the Xplore-2 Study
Jun 13, 2018: Xeltis restorative technology for aortic valves at ISMICS
Jun 01, 2018: Preliminary Xplore-1 data show promise at ECHSA
May 30, 2018: Preliminary Xplore-1 data at ECHSA
May 22, 2018: Xeltis aortic valve program in focus at EuroPCR
May 14, 2018: Xeltis’ restorative technology at ICTEHV
Apr 13, 2018: Xeltis’ restorative aortic valves show promise at HVS
Apr 06, 2018: Xeltis’ restorative aortic valves at HVS
Nov 01, 2017: Xeltis’ Aortic Valve Preclinical Results Shared at TCT 2017
Appendix
Methodology
About the Publisher
Contact
Disclaimer

List of Tables
Xeltis AG Pipeline Products and Ongoing Clinical Trials Overview
Xeltis AG Pipeline Products by Equipment Type
Xeltis AG Pipeline Products by Indication
Xeltis AG Ongoing Clinical Trials by Trial Status
Xeltis AG, Key Facts
Xeltis AG, Major Products and Services
Xeltis AG Number of Pipeline Products by Development Stage
Xeltis AG Pipeline Products Summary by Development Stage
Xeltis AG Ongoing Clinical Trials by Trial Status
Xeltis AG Ongoing Clinical Trials Summary
Endogenous Tissue Restoration (ETR) Cardiovascular Graft - Product Status
Endogenous Tissue Restoration (ETR) Cardiovascular Graft - Product Description
Transcatheter Aortic Heart Valve - Product Status
Transcatheter Aortic Heart Valve - Product Description
Xeltis Pulmonary Valve - Product Status
Xeltis Pulmonary Valve - Product Description
Xeltis Pulmonary Valve - Initial Safety and Performance of the COR-VP-001 Vascular Patch in Pediatric Patients Undergoing Bidirectional Cava-pulmonary Anastomosis
Xeltis Pulmonary Valve - Prospective, Non-randomized, Open Label Clinical Study to Assess the Feasibility of the Bioabsorbable Pulmonary Valved Conduit in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction
Xeltis Pulmonary Valve - Prospective, Non-randomized, Open Label Clinical Study to Assess the Safety and Performance of the Bioabsorbable Pulmonary Valved Conduit in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction
Xeltis Pulmonary Valve - Prospective, Non-randomized, Open Label Clinical Study to Assess the Safety of the Bioabsorbable Pulmonary Valved Conduit (PV-001) in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction
Xeltis AG, Key Employees
Xeltis AG, Subsidiaries
Glossary

List of Figures
Xeltis AG Pipeline Products by Equipment Type
Xeltis AG Pipeline Products by Development Stage
Xeltis AG Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abionic SA
  • Sequana Medical AG
  • Symetis SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll